Streetbeat News

Products Services

BCTX

BriaCell Therapeutics Corp. (NASDAQ:BCTX) has initiated a first-in-human, Phase 1/2 study to evaluate the safety and efficacy of Bria-OTS™, its personalized off-the-shelf next-generation immunotherapy, in advanced metastatic breast cancer. The study will assess Bria-OTS™ as a monotherapy and in combination with the PD-1 inhibitor tislelizumab.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:09 pm

CBRL

Cracker Barrel has updated its fiscal 2024 outlook, expecting total revenue between $3.47 billion and $3.51 billion, slightly lower than the previous estimate. The company also projects adjusted EBITDA of $200 million to $220 million and plans to open new stores.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:09 pm

OPTX

Syntec Optics (NASDAQ:OPTX) has secured an order to develop a high-resolution and high numerical aperture lens system for next-generation digital night vision. The terms of the transaction were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:08 pm

ALUR

Allurion has announced an update to its Coach Iris, which will now include 24/7 coaching and guidance. This enhancement aims to provide continuous support to users, potentially increasing user engagement and satisfaction.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:08 pm

LCID

Hyundai Motor Company is reportedly considering a partnership with Lucid Group for high-performance electric motors. Hyundai's CEO visited Lucid's headquarters to discuss cooperation, potentially incorporating Lucid's motors into Hyundai's luxury brand Genesis. Lucid recently partnered with Aston Martin for similar purposes. Despite financial challenges, Lucid has significant liquidity to sustain operations through 2025.

Portfolio Pulse from Anan Ashraf

May 30, 2024 | 12:07 pm

FDMT

4D Molecular Therapeutics (NASDAQ: FDMT) will present interim data from its Phase 1/2 AEROW clinical trial for aerosolized 4D-710, aimed at treating cystic fibrosis lung disease, at the 47th European Cystic Fibrosis Conference on June 6, 2024. The company will also host a webcast to discuss the data and provide a program update.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:07 pm

NXPI

NXP Semiconductors, eleQtron, and ParityQC have unveiled the first full-stack, ion-trap based quantum computer demonstrator in Germany, commissioned by the DLR Quantum Computing Initiative. This demonstrator aims to enhance quantum expertise and will be accessible to industry and academia.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:04 pm

CADL

Candel Therapeutics announced that the FDA has granted Orphan Drug Designation to its oncolytic viral immunotherapy, CAN-3110, for the treatment of recurrent high-grade glioma.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:04 pm

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) has introduced its Modular and Fast Track viral vector technology transfer frameworks to accelerate gene therapy development. The program aims to ensure seamless process transfer to its Maryland-based viral vector Center of Excellence within nine months.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:03 pm

MNTS

Momentus has received a contract from DARPA to support the design and in-space demonstration of large-scale space structures.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:02 pm